3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
12
Waldenstrom Macroglobulinemia
6
Lymphoma, Follicular
6
Lymphoma, Non-Hodgkin
3
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Lymphoma, Mantle-Cell
1
Leukemia, Prolymphocytic
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Hodgkin Disease
1
Colorectal Neoplasms
1
Interventions
Bevacizumab
234
Fluorouracil
220
Oxaliplatin
216
Irinotecan
215
Leucovorin
199
Capecitabine
153
Cetuximab
146
Panitumumab
70
Folfox protocol
51
regorafenib
43
Radiotherapy
38
pembrolizumab
37
IFL protocol
36
HMPL-013
36
trifluridine tipiracil drug combination
32
Nivolumab
32
Drug Therapy
26
Neoadjuvant Therapy
24
Trifluridine
18
Celecoxib
18
tislelizumab
17
XELOX
17
sintilimab
16
Trastuzumab
16
durvalumab
15
atezolizumab
15
aflibercept
15
Chemotherapy, Adjuvant
15
Biopsy
15
apatinib
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Colorectal Neoplasms
×
idelalisib
×
Clear all
NCT05725200
2023-02-21
EVIDENT
Oslo University Hospital
Phase 2
Recruiting
40 enrolled